Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against PDE5A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

• 2025-02-21Results posted on the registry: Rutgers, The State University of New Jersey, Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care (NCT04410328)
• 2025-02-04Also stopped (terminated): Actelion, Inhaled Iloprost (5 μg) + Inhaled Placebo (NCT00302211)
• 2025-02-03Phase 3 first posted: Sanofi, Tadalafil 5 mg tablets with a digital tool. (NCT06805513)
• 2025-01-30Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Tadalafil + Pembrolizumab (NCT05014776)
• 2025-01-29Phase 3 first posted: The University of Texas Medical Branch, Galveston, Sildenafil (NCT06800092)
• 2024-12-06Also stopped (withdrawn): Universidad del Norte, Sildenafil Injectable Product (NCT04912726)
• 2024-12-05Phase 3 first posted: Regina Elena Cancer Institute, PDE5 inhibitor (tadalafil) (NCT06717711)
• 2024-11-27Phase 3 first posted: Beni-Suef University, • The study will include 180 randomly selected patients who met inclusion criteria were randomized into four groups: silodosin 8 mg (Group A), tamsulosin 0.4 mg (Group B), silodosin 8 mg plus tadalaf (NCT06707181)
• 2024-11-27Results posted on the registry: University of California, Los Angeles, Ibudilast + Placebo oral capsule (NCT03594435)
• 2024-10-30Results posted on the registry: MediciNova, Ibudilast + Placebo (NCT04429555)
• 2024-10-15Results posted on the registry: University of Missouri-Columbia, Pentoxifylline + Placebo (NCT02592863)
• 2024-10-15Also stopped (terminated): University of Missouri-Columbia, Pentoxifylline + Placebo (NCT02592863)
• 2024-10-01Results posted on the registry: Philips Clinical & Medical Affairs Global, a drug against PDE5A (NCT04696354)
• 2024-09-25Also stopped (terminated): Iain Bressendorff, ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib (NCT05897372)
• 2024-09-24Results posted on the registry: MediciNova, ibudilast + Ibudilast (NCT02714036)
• 2024-09-23Results posted on the registry: Boston Medical Group, a drug against PDE5A (NCT03596047)
• 2024-09-04Phase 3 first posted: Aswan University Hospital, Botulinum toxin A + Tadalafil 5mg (NCT06583590)
• 2024-08-02Results posted on the registry: Shionogi, MT-1186 + Rosuvastatin (NCT04481789)
• 2024-07-26Phase 3 first posted: University of Alabama at Birmingham, Sildenafil 50 mg Oral Tablet + Placebo Oral Tablet (NCT06522854)
• 2024-07-25Phase 3 first posted: University Medical Centre Ljubljana, Tadalafil 5mg (NCT06520839)
• 2024-07-10Results posted on the registry: Montefiore Medical Center, Sildenafil + Placebo Oral Tablet (NCT03199612)
• 2024-07-08Phase 3 first posted: Tanta University, Vardenafil 5 Mg Oral Tablet (NCT06491108)
• 2024-06-20Phase 3 first posted: Al-Azhar University, Tadalafil (NCT06466369)
• 2024-05-20Phase 3 first posted: Ain Shams University, Dapagliflozin 10mg Tab + Pentoxifylline 400 MG (NCT06421870)
• 2024-05-20Phase 3 first posted: Tanta University, Pentoxifylline + Probiotic Formula (NCT06422000)

What is not public

• Internal portfolio and board discussions
• Unpublished trial data and interim analyses
• Terms of any partner or licence decision